Citius Pharmaceuticals, Inc.
CTXR
$0.968
-$0.021-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.77% | 12.34% | 60.38% | 23.60% | 76.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.48% | 9.14% | 22.63% | 2.67% | 28.84% |
| Operating Income | -7.48% | -9.14% | -22.63% | -2.67% | -28.84% |
| Income Before Tax | -10.23% | -11.56% | -25.12% | 19.09% | -163.43% |
| Income Tax Expenses | 83.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -11.37% | -11.40% | -24.70% | 18.83% | -156.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.82% | -8.51% | -24.70% | 18.83% | -156.88% |
| EBIT | -7.48% | -9.14% | -22.63% | -2.67% | -28.84% |
| EBITDA | -7.48% | -9.15% | -22.63% | -2.67% | -28.84% |
| EPS Basic | 10.20% | 8.79% | -13.65% | 25.37% | -136.26% |
| Normalized Basic EPS | 14.12% | 6.07% | -10.67% | 4.46% | -18.81% |
| EPS Diluted | 10.20% | 4.92% | -4.44% | 25.37% | -136.26% |
| Normalized Diluted EPS | 14.12% | 6.07% | -10.67% | 4.46% | -18.81% |
| Average Basic Shares Outstanding | 17.84% | 13.79% | 13.06% | 8.77% | 8.72% |
| Average Diluted Shares Outstanding | 17.84% | 13.79% | 13.06% | 8.77% | 8.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |